Taurodeoxycholic acid (sodium hydrate)

Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway[1].

Product Specifications

CAS Number

[110026-03-4]

Product Name Alternative

Taurodeoxycholate (sodium hydrate)

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Endogenous Metabolite; G protein-coupled Bile Acid Receptor 1

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/taurodeoxychloic-acid-sodium-hydrate.html

Purity

99.75

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C.O

Molecular Formula

C26H46NNaO7S

Molecular Weight

539.70

Precautions

H302, H315, H319, H335

References & Citations

[1]Chang S, et al. Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice. Front Immunol. 2018 Sep 18;9:1984.|[2]Yamaguchi J, et al. Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression. Surgery. 2004 Feb;135 (2) :215-21.